BUSINESS WATCH

摘要

Companies are racing to produce treatments that exploit RNA interference (RNAi), a natural process that silences gene expression in cells. PharmaVision, a biomedical consultancy based in Chichester, UK, estimates that the market for RNAi therapies could be worth more than US$2.9 billion by 2020. But no RNAi therapy has yet completed phase III clinical trials. Results from a phase Ib trial of an RNAi therapy developed by a consortium including TransDerm of Santa Cruz, California, were published on 24 November .